Equity
€784,088 ▲ 10.1%
Danis Pharma has made a profit without a break since 2020.
Danis Pharma
Lifetime
19 annual accounts with figures on one time axis, 26 filings since 2000peak €162,510 (2021)
€113,647▼ 8.8%
lowest -€31,065 (2019)
€71,707▼ 12.9%
peak €784,088 (2025)
€784,088▲ 10.1%
€82,012▼ 23.4%
peak 0.8 FTE (2007)
-not published
Board2 names since 2017
2 directorsDanuta Osiadacz and 1 other
Owners
98.8%Maasdender
Documentsfilings and deeds
29-01-20262 days before the deadline
2025abbreviated format
Debts from €107,096 to €82,012Cash from €143,690 to €69,907
Key points
from the 2025 annual accountsTurnover
≈ €530,000 estimated
The abbreviated format states no turnover.
Position in the sector
90.5%
Higher solvency than 95% of companies in retail trade. Sector median 36.6% · 12,856 companies.
Checked score
97
Excellent
Financially stronger than 72% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: 0.1%▲ +0.1 percentage points vs 01-2025highest value
03-2025: < 0.1%▼ -0.1 percentage points vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025lowest value
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: 0.1%▲ +0.1 percentage points vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Sector: Retail trade (NACE 47)
lowers risk
Founded in 1999
Equity €784,088 (90.5% of total assets)
Size: total assets €866,100
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 92% of them on solvency, 67% on liquidity, 69% on profitability and 61% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-06-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,137 companies had the same profile as Danis Pharma has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
That fits the bankruptcy probability of Danis Pharma itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,137 companies, not a prediction for Danis Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €75,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 9.88 (6.96 in 2024), above the usual 1.5. Short-term debt is 8.8% and cash 8.1% of total assets. 9.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 29-01-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 days early
2024
21 days late
2023
1 day early
2022
1 day early
2021
41 days early
2020
2 days early
2019
10 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 5 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 30 January (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end10-11-2026 today31-01-2027 deadline
Board and ownership
- Maasdender 98.8%equity €28,333 (2026) · 31-03-2026 annual accounts of Maasdender
Recent changes
Reappointments: Philippe Vanneste (director) and Danuta Osiadacz (director)
General meeting of 21-12-2023 · Gazette deed
Reappointments: Vanneste Philippe (director) and Osiadacz Danuta (managing director)
General meeting of 02-12-2017 · Gazette deed
First establishment
Danislaan 13, Beersel
Incorporation
published on 04-02-1999 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Danis Pharma Beersel | €866,100 | €113,647 | 90.5% | - |
| APOTHEEK DE STERRE Ghent | €863,882 | €128,250 | 17.8% | 0 |
| PHARMANEMA Leuven | €910,021 | €114,505 | 39.3% | - |
| APOTHEEK VAN GLABEKE Eeklo | €763,636 | €104,967 | 25.4% | 0 |
| APOTHEEK VANTHOOR - VANKEVELAER Oudsbergen | €881,195 | €134,046 | 68.7% | - |
| Apotheek Wyseur Beernem | €932,853 | €133,491 | 87.7% | 1.5 |
| APOTHEEK A.VANTIEGHEM Aalst | €891,606 | €139,175 | 31.1% | 1 |
These companies have the same main activity as Danis Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €764,000 and €933,000, founded between 1995 and 2002.
Official details
Source: KBO- Status
- Active since 27-01-1999Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.091.904.6711650 Beersel, since 31-10-2000
- Financial year end
- 30 June
- Peppol
- Reachable
Annual accounts to 30-06-2025
- €866,100▲ 5.7%
- Filing
- Filed on 29-01-2026, 2 days before the end of the filing period
Insights on Danis Pharma
Danis Pharma files the abbreviated format. That format states no turnover. The gross margin rose from €96,675 in 2007 to €113,647 in 2025.
Maasdender holds 98.8% of the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Danis Pharma
- What is the company number of Danis Pharma?
- The company number of Danis Pharma is 0465.345.721. The VAT number is the same number with BE in front: BE 0465.345.721.
- Where is Danis Pharma based?
- The registered office is at Danislaan 13, 1650 Beersel.Company details
- What does Danis Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Danis Pharma?
- Danis Pharma is a public limited company (NV).
- When was Danis Pharma founded?
- Danis Pharma was founded on 27-01-1999.
- Is Danis Pharma still active?
- Yes, Danis Pharma is an active enterprise in the KBO register.
- What is the turnover of Danis Pharma?
- The turnover in financial year 2025 is ≈ €530,000. This figure is estimated from the gross margin of €113,647 and 51 comparable companies (NACE 477). It probably lies between €360,000 and €1.0m.Financials
- Is Danis Pharma profitable?
- In financial year 2025, Danis Pharma made a profit of €71,707.
- Where can I find the annual accounts of Danis Pharma?
- Danis Pharma filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Danis Pharma due?
- Danis Pharma must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.